PL2053050T3 - Podobny do aspalatyny dihydrochalkon i sposób jego wytwarzania - Google Patents
Podobny do aspalatyny dihydrochalkon i sposób jego wytwarzaniaInfo
- Publication number
- PL2053050T3 PL2053050T3 PL07020728T PL07020728T PL2053050T3 PL 2053050 T3 PL2053050 T3 PL 2053050T3 PL 07020728 T PL07020728 T PL 07020728T PL 07020728 T PL07020728 T PL 07020728T PL 2053050 T3 PL2053050 T3 PL 2053050T3
- Authority
- PL
- Poland
- Prior art keywords
- trihydroxy
- phenyl
- aspalathin
- dihydrochalcone
- manufacture
- Prior art date
Links
- VCPUQYKWJRESOC-VJXVFPJBSA-N aspalathin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C(C(=O)CCC=2C=C(O)C(O)=CC=2)=C1O VCPUQYKWJRESOC-VJXVFPJBSA-N 0.000 title 1
- VCPUQYKWJRESOC-UHFFFAOYSA-N aspalathine Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(O)C(C(=O)CCC=2C=C(O)C(O)=CC=2)=C1O VCPUQYKWJRESOC-UHFFFAOYSA-N 0.000 title 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 title 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 240000006914 Aspalathus linearis Species 0.000 abstract 2
- AKGDIVKDYFDRLS-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-[3-[2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2h-chromen-4-yl]-2,4,6-trihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]propan-1-one Chemical compound OC1C(O)C(O)C(CO)OC1C1=C(O)C(C2C3=C(O)C=C(O)C=C3OC(C2O)C=2C=C(O)C(O)=CC=2)=C(O)C(C(=O)CCC=2C=C(O)C(O)=CC=2)=C1O AKGDIVKDYFDRLS-UHFFFAOYSA-N 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000000701 neuroleptic effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07020728A EP2053050B1 (de) | 2007-10-23 | 2007-10-23 | Aspalathin-ähnliches Dihydrochalcon und Verfahren zur Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2053050T3 true PL2053050T3 (pl) | 2012-01-31 |
Family
ID=38805677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07020728T PL2053050T3 (pl) | 2007-10-23 | 2007-10-23 | Podobny do aspalatyny dihydrochalkon i sposób jego wytwarzania |
| PL08801873T PL2069334T5 (pl) | 2007-10-23 | 2008-09-05 | Aspalatyno-podobny dihydrochalkon, wyciągi z niefermentowanego czerwonokrzewu i sposób wytwarzania |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08801873T PL2069334T5 (pl) | 2007-10-23 | 2008-09-05 | Aspalatyno-podobny dihydrochalkon, wyciągi z niefermentowanego czerwonokrzewu i sposób wytwarzania |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100222423A1 (enExample) |
| EP (2) | EP2053050B1 (enExample) |
| JP (1) | JP5527900B2 (enExample) |
| AT (2) | ATE522524T1 (enExample) |
| DK (2) | DK2053050T3 (enExample) |
| ES (2) | ES2372203T3 (enExample) |
| HR (1) | HRP20110890T4 (enExample) |
| PL (2) | PL2053050T3 (enExample) |
| PT (2) | PT2053050E (enExample) |
| WO (1) | WO2009052895A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520913A (ja) | 2007-03-12 | 2010-06-17 | サズセ アーペーエス | ルイボスの抗糖尿病性抽出物 |
| JP6797408B2 (ja) | 2014-11-06 | 2020-12-09 | 国立大学法人 長崎大学 | 新規アルツハイマー病治療薬 |
| JP6735224B2 (ja) | 2016-01-28 | 2020-08-05 | 花王株式会社 | アストロサイトのグルコース代謝活性化剤 |
| JP7244273B2 (ja) * | 2018-12-27 | 2023-03-22 | 株式会社 伊藤園 | ルイボス茶飲料の製造方法 |
| CN109932448A (zh) * | 2019-03-29 | 2019-06-25 | 完美（广东）日用品有限公司 | 一种线叶金雀花及其制品中有效成分的含量测定方法 |
| CN115104730A (zh) * | 2022-06-28 | 2022-09-27 | 北京姿美堂生物技术股份有限公司 | 一种改善睡眠的组合物、线叶金雀花-芦笋睡眠改善液、茶粉的制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2895298B2 (ja) * | 1991-12-27 | 1999-05-24 | 株式会社ユニエ | 活性酸素消去・除去剤 |
| JPH05246866A (ja) * | 1992-03-06 | 1993-09-24 | Ruibosuteii Japan:Kk | 脳代謝促進・脳機能改善剤 |
| JPH11116429A (ja) † | 1997-10-13 | 1999-04-27 | Mikimoto Pharmaceut Co Ltd | 化粧品原料および化粧品 |
| JP2001316239A (ja) * | 2000-05-10 | 2001-11-13 | Mikimoto Pharmaceut Co Ltd | 皮膚外用剤 |
| KR100421233B1 (ko) * | 2001-09-10 | 2004-03-11 | 한국원자력연구소 | 식품, 의약품 및 화장품 제조용 천연물의 색도 개선 방법 및 이의 방법에 의해 색도가 개선된 천연물 추출물 |
| ZA200303674B (en) * | 2002-02-20 | 2005-04-26 | Benedict Technology Holdings P | Antioxidant composition. |
| JP4637491B2 (ja) * | 2004-03-01 | 2011-02-23 | 株式会社東洋発酵 | 抗アレルギー用組成物 |
| DE102004052800B4 (de) * | 2004-10-30 | 2017-02-23 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Verbesserte Trägerformulierungen |
| DE102005004438B4 (de) * | 2005-01-31 | 2007-12-20 | Raps Gmbh & Co. Kg | Rooibos-Extrakt mit erhöhtem Aspalathingehalt, Verfahren zur Herstellung eines solchen Rooibos-Extraktes und kosmetisches Mittel enthaltend einen solchen Rooibos-Extrakt |
| JP2007161661A (ja) * | 2005-12-15 | 2007-06-28 | Pola Chem Ind Inc | アドバンスド・グリケーション・エンドプロダクツを分解するための化粧料とその製造法 |
| JP2010520913A (ja) † | 2007-03-12 | 2010-06-17 | サズセ アーペーエス | ルイボスの抗糖尿病性抽出物 |
-
2007
- 2007-10-23 PL PL07020728T patent/PL2053050T3/pl unknown
- 2007-10-23 AT AT07020728T patent/ATE522524T1/de active
- 2007-10-23 DK DK07020728.7T patent/DK2053050T3/da active
- 2007-10-23 EP EP07020728A patent/EP2053050B1/de not_active Not-in-force
- 2007-10-23 ES ES07020728T patent/ES2372203T3/es active Active
- 2007-10-23 PT PT07020728T patent/PT2053050E/pt unknown
-
2008
- 2008-09-05 EP EP08801873.4A patent/EP2069334B2/de not_active Not-in-force
- 2008-09-05 PL PL08801873T patent/PL2069334T5/pl unknown
- 2008-09-05 WO PCT/EP2008/007279 patent/WO2009052895A1/de not_active Ceased
- 2008-09-05 AT AT08801873T patent/ATE533763T1/de active
- 2008-09-05 DK DK08801873.4T patent/DK2069334T4/da active
- 2008-09-05 HR HRP20110890AT patent/HRP20110890T4/hr unknown
- 2008-09-05 PT PT08801873T patent/PT2069334E/pt unknown
- 2008-09-05 JP JP2010530290A patent/JP5527900B2/ja not_active Expired - Fee Related
- 2008-09-05 ES ES08801873.4T patent/ES2373509T5/es active Active
- 2008-09-05 US US12/739,280 patent/US20100222423A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL2069334T3 (pl) | 2012-04-30 |
| US20100222423A1 (en) | 2010-09-02 |
| PT2053050E (pt) | 2011-12-09 |
| ATE533763T1 (de) | 2011-12-15 |
| PL2069334T5 (pl) | 2015-06-30 |
| JP5527900B2 (ja) | 2014-06-25 |
| HRP20110890T4 (xx) | 2015-02-27 |
| EP2069334B1 (de) | 2011-11-16 |
| EP2069334B2 (de) | 2014-11-05 |
| EP2053050A1 (de) | 2009-04-29 |
| ATE522524T1 (de) | 2011-09-15 |
| ES2372203T3 (es) | 2012-01-17 |
| PT2069334E (pt) | 2011-12-30 |
| ES2373509T5 (es) | 2015-02-16 |
| WO2009052895A1 (de) | 2009-04-30 |
| DK2069334T3 (da) | 2012-01-23 |
| ES2373509T3 (es) | 2012-02-06 |
| DK2053050T3 (da) | 2011-11-21 |
| DK2069334T4 (da) | 2014-12-08 |
| EP2053050B1 (de) | 2011-08-31 |
| EP2069334A1 (de) | 2009-06-17 |
| JP2011501755A (ja) | 2011-01-13 |
| HRP20110890T1 (hr) | 2011-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2053050T3 (pl) | Podobny do aspalatyny dihydrochalkon i sposób jego wytwarzania | |
| EG25488A (en) | Fungicidal mixtures of thiophene derivative | |
| EP2178869A4 (en) | INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS | |
| MX2010003711A (es) | Derivados de tetrahidroquinolina para tratar trastornos por estres post-traumatico. | |
| NZ600210A (en) | Substituted 4-aminocyclohexane derivatives | |
| EP3210633A3 (en) | Compositions and their uses directed to huntingtin | |
| MY148844A (en) | Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol | |
| NZ593622A (en) | Galenic formulations of organic compounds | |
| MX2007013623A (es) | Preparacion externa para la piel. | |
| EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| EP2345326A3 (en) | Fly attractant composition containing a ligninsulfonate as active agent | |
| MX2012005329A (es) | Compuestos benzoimidazolicos y sus usos. | |
| EP2146688A4 (en) | COSMETIC COMPOSITION FOR LIGHTING UP THE SKIN WITH MAGNOLIA SIEBOLDII EXTRACT AS AN ACTIVE SUBSTANCE | |
| EP2153834A3 (en) | Extended release pharmaceutical compositions comprising quetiapine salts | |
| NZ592543A (en) | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | |
| WO2011021892A3 (ko) | 헥사미딘류 및 레티노이드류를 함유하는 피부 개선 조성물 | |
| WO2009038412A3 (en) | Beta-secretase inhibiting compounds | |
| PE20020351A1 (es) | Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 | |
| ZA200809111B (en) | Substituted carboxamides | |
| TW200716184A (en) | Inhibitor for parakeratosis, pore reducing agent or skin roughening preventing or ameliorating agent and composition for skin care preparation | |
| WO2011075799A3 (en) | Oral antidepressant formulation | |
| WO2009108017A3 (en) | New pyruvate derivatives with neuroprotective effect, process for preparing the same and pharmaceutical composition comprising the same | |
| WO2009038411A3 (en) | Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety | |
| WO2008022745A8 (de) | Formulierungen zur kontrollierten freisetzung agrochemischer wirkstoffe | |
| RU2015126345A (ru) | Фармацевтическая композиция n-[5-[2-(3,5-диметоксифенил)этил]-2н-пиразол-3-ил]-4-[(3r,5s)-3,5-диметилпиперазин-1-ил]бензамида |